David R Andes

List of Articles by Year
in descending order

243 PR articles	25,866 PR citations	8894 70 PR h-index	6419 155 g-index
290 documents	30837 doc citations	8245 77 h-index	27467 citing authors

#	Article	IF	Citations
1	The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics. Journal of Antimicrobial Chemotherapy, 2025, 80, 18-28.	3.1	12
2	Genetic interaction analysis of Candida glabrata transcription factors CST6 and UPC2A	4.1	1
3	A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response. Science Translational Medicine, 2025, 17, .	12.5	5
4	Candida albicans biofilm extracellular vesicles deliver candidalysin to epithelial cell membranes and induce host cell responses. Infection and Immunity, 2025, 93, .	2.7	6
5	Activity of rezafungin against Candida auris. Journal of Antimicrobial Chemotherapy, 2025, 80, 1482-1493.	3.1	2
6	Nanoemulsion-based nanoplatform as a new PEITC nano - delivery system to pancreatic cancer cells. Journal of Drug Delivery Science and Technology, 2025, 110, 106987.	3.2	1
7	Adhesin Als4112 promotes Candida auris skin colonization through interactions with keratinocytes and extracellular matrix proteins. Nature Communications, 2025, 16, .	13.7	6
8	Liposomal formulation of a new antifungal hybrid compound provides protection against Candida auris in the ex vivo skin colonization model. Antimicrobial Agents and Chemotherapy, 2024, 68, .	4.1	17
9	Candida albicans extracellular vesicles trigger type I IFN signalling via cGAS and STING. Nature Microbiology, 2024, 9, 95-107.	16.0	57
10	Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies. Open Forum Infectious Diseases, 2024, 11, .	0.8	16
11	In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model. Antimicrobial Agents and Chemotherapy, 2024, 68, .	4.1	9
12	Secretion of the fungal toxin candidalysin is dependent on conserved precursor peptide sequences. Nature Microbiology, 2024, 9, 669-683.	16.0	15
13	Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial Agents and Chemotherapy, 2024, 68, .	4.1	21
14	Biofilm-associated metabolism via ERG251 in Candida albicans. PLoS Pathogens, 2024, 20, e1012225.	4.4	12
15	Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing. Clinical Infectious Diseases, 2024, 79, 1354-1362.	5.2	3
16	Metabolic reprogramming during Candida albicans planktonic-biofilm transition is modulated by the transcription factors Zcf15 and Zcf26. PLoS Biology, 2024, 22, e3002693.	5.0	7
17	Systematic analysis of the Candida albicans kinome reveals environmentally contingent protein kinase-mediated regulation of filamentation and biofilm formation in vitro	4.4	7
18	In vivo and pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models. Antimicrobial Agents and Chemotherapy, 2024, 68, .	4.1	3

#	Article	IF	Citations
19	Reinforcement amid genetic diversity in the Candida albicans biofilm regulatory network. PLoS Pathogens, 2023, 19, e1011109.	4.4	30
20	Under-oil open microfluidic systems for rapid phenotypic antimicrobial susceptibility testing. Lab on A Chip, 2023, 23, 2005-2015.	5.1	19
21	Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches. Antimicrobial Agents and Chemotherapy, 2023, 67, .	4.1	11
22	Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints. Journal of Antimicrobial Chemotherapy, 2023, 78, 1386-1394.	3.1	2
23	Novel Keto-Alkyl-Pyridinium Antifungal Molecules Active In Models of In Vivo Candida albicans Vascular Catheter Infection and Ex Vivo Candida auris Skin Colonization. Antimicrobial Agents and Chemotherapy, 2023, 67, .	4.1	8
24	Identification of triazenyl indoles as inhibitors of fungal fatty acid biosynthesis with broad-spectrum activity. Cell Chemical Biology, 2023, 30, 795-810.e8.	6.2	23
25	Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2023, 43, 1043-1050.	2.8	68
26	The Candida albicans reference strain SC5314 contains a rare, dominant allele of the transcription factor Rob1 that modulates filamentation, biofilm formation, and oral commensalism. MBio, 2023, 14, .	4.4	30
27	A Candida auris â€“specific adhesin, Scf1, governs surface association, colonization, and virulence. Science, 2023, 381, 1461-1467.	36.2	90
28	Role of the extracellular matrix in Candida biofilm antifungal resistance. FEMS Microbiology Reviews, 2023, 47, .	10.6	23
29	Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal. Nature, 2023, 623, 1079-1085.	37.9	82
30	Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived Pseudonocardia sp. Bacterium. Organic Letters, 2022, 24, 3998-4002.	4.8	13
31	Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation. Nature Communications, 2022, 13, .	13.7	41
32	Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains. Microbiology Spectrum, 2022, 10, .	3.6	8
33	A common vesicle proteome drives fungal biofilm development. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.5	48
34	Structural and functional analysis of EntV reveals a 12 amino acid fragment protective against fungal infections. Nature Communications, 2022, 13, .	13.7	25
35	Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. Drug Discovery Today, 2021, 26, 31-43.	6.6	55
36	The protein kinase Ire1 impacts pathogenicity of Candida albicans by regulating homeostatic adaptation to endoplasmic reticulum stress. Cellular Microbiology, 2021, 23, .	1.6	29

#	Article	IF	Citations
37	Chemical Exchanges between Multilateral Symbionts. Organic Letters, 2021, 23, 1648-1652.	4.8	21
38	Formation and characterization of biofilms formed by salt-tolerant yeast strains in seawater-based growth medium. Applied Microbiology and Biotechnology, 2021, 105, 2411-2426.	4.0	10
39	Turbinmicin inhibits Candida biofilm growth by disrupting fungal vesicleâ€“mediated trafficking. Journal of Clinical Investigation, 2021, 131, .	10.6	53
40	Modelâ€Informed Drug Development for Antiâ€Infectives: State of the Art and Future. Clinical Pharmacology and Therapeutics, 2021, 109, 867-891.	4.7	64
41	The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	4.1	7
42	Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. Current Opinion in Infectious Diseases, 2021, 34, 288-296.	3.4	10
43	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. American Journal of Health-System Pharmacy, 2021, 78, 2256-2264.	1.0	12
44	Regulatory Level of Evidence and Practicality in Antifungal Use Decisions for Less Common Fungal Diseases. Clinical Infectious Diseases, 2021, 73, 2341-2343.	5.2	2
45	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infectious Diseases, The, 2021, 21, e364-e374.	16.5	227
46	Specialized Metabolites Reveal Evolutionary History and Geographic Dispersion of a Multilateral Symbiosis. ACS Central Science, 2021, 7, 292-299.	9.2	34
47	A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase. Nature Communications, 2021, 12, .	13.7	99
48	Coordination of fungal biofilm development by extracellular vesicle cargo. Nature Communications, 2021, 12, .	13.7	99
49	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus. Pharmaceutics, 2021, 13, 1791.	4.9	18
50	Continuous flow synthesis and antimicrobial evaluation of NHC* silver carboxylate derivatives of SBC3 in vitro and in vivo. Metallomics, 2021, 13, .	2.6	11
51	A Label-Free Cellular Proteomics Approach to Decipher the Antifungal Action of DiMIQ, a Potent Indolo[2,3-b]Quinoline Agent, against Candida albicans Biofilms. International Journal of Molecular Sciences, 2021, 22, 108.	4.4	6
52	Preventing Pseudomonas aeruginosa Biofilms on Indwelling Catheters by Surface-Bound Enzymes. ACS Applied Bio Materials, 2021, 4, 8248-8258.	4.7	31
53	Candidemia in the Growing Opioid Epidemic: A Distinct and Emerging Entity. Clinical Infectious Diseases, 2020, 71, 1738-1740.	5.2	2
54	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.2	2,343

#	Article	IF	Citations
55	Biomineral armor in leaf-cutter ants. Nature Communications, 2020, 11, .	13.7	53
56	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. Journal of Infectious Diseases, 2020, 222, S175-S198.	3.8	142
57	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. Journal of Antimicrobial Chemotherapy, 2020, 75, 3023-3028.	3.1	17
58	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2020, 64, .	4.1	41
59	An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris. Nature Communications, 2020, 11, .	13.7	67
60	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	4.1	5
61	Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo -Lactamase-1. Marine Drugs, 2020, 18, 295.	5.2	8
62	Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. Open Forum Infectious Diseases, 2020, 7, .	0.8	14
63	Contributions of the Biofilm Matrix to Candida Pathogenesis. Journal of Fungi (Basel, Switzerland), 2020, 6, 21.	3.5	111
64	A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation. Transplant Infectious Disease, 2019, 21, .	2.2	13
65	The Candida albicans biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation. PLoS Biology, 2019, 17, e3000422.	5.0	29
66	Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis. PLoS ONE, 2019, 14, e0221228.	2.3	6
67	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2019, 74, 3056-3062.	3.1	82
68	Pyonitrins Aâ€“D: Chimeric Natural Products Produced by Pseudomonas protegens. Journal of the American Chemical Society, 2019, 141, 17098-17101.	15.0	38
69	In vivopharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2019, 74, iii5-iii10.	3.1	29
70	In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	4.1	11
71	Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. Journal of Biological Chemistry, 2019, 294, 2700-5412.	2.2	22
72	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	4.1	45

#	Article	IF	Citations
73	The antimicrobial potential of Streptomyces from insect microbiomes. Nature Communications, 2019, 10, .	13.7	302
74	Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. Infectious Disease Clinics of North America, 2019, 33, 399-445.	3.2	24
75	Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical Î²-Peptides To Prevent Candida albicans Biofilm Formation. Antimicrobial Agents and Chemotherapy, 2019, 63, .	4.1	8
76	WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-Î²-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	4.1	29
77	Variability and exposureâ€“response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. Journal of Antimicrobial Chemotherapy, 2019, 74, 761-767.	3.1	67
78	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	4.1	16
79	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	4.1	23
80	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. Clinical Infectious Diseases, 2019, 68, 850-853.	5.2	41
81	Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?. Clinical Infectious Diseases, 2019, 68, 1990-1992.	5.2	6
82	Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. ISME Journal, 2018, 12, 1427-1442.	9.1	136
83	Pharmacokineticsâ€“pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. Diagnostic Microbiology and Infectious Disease, 2018, 91, 371-382.	1.6	8
84	Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. MBio, 2018, 9, .	4.4	69
85	In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	4.1	61
86	We can do better: a fresh look at echinocandin dosing. Journal of Antimicrobial Chemotherapy, 2018, 73, i44-i50.	3.1	42
87	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN). Open Forum Infectious Diseases, 2018, 5, S426-S426.	0.8	1
88	406. Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients With Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT). Open Forum Infectious Diseases, 2018, 5, S156-S156.	0.8	0
89	Candidaâ€“streptococcal interactions in biofilm-associated oral diseases. PLoS Pathogens, 2018, 14, e1007342.	4.4	131
90	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	3.0	112

#	Article	IF	Citations
91	In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	4.1	14
92	Topical Delivery of Ebselen Encapsulated in Biopolymeric Nanocapsules: Drug Repurposing Enhanced Antifungal Activity. Nanomedicine, 2018, 13, 1139-1155.	3.0	40
93	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. Antimicrobial Agents and Chemotherapy, 2018, 62, .	4.1	61
94	In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	48
95	Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation. Pharmaceutical Research, 2017, 34, 1115-1124.	3.7	14
96	In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	94
97	In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	40
98	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	25
99	Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection. Open Forum Infectious Diseases, 2017, 4, S73-S73.	0.8	1
100	In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Current Opinion in Pharmacology, 2017, 36, 94-99.	3.8	49
101	Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	34
102	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	105
103	Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation inCandida albicans. Cellular Microbiology, 2017, 19, e12767.	1.6	21
104	The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus. Journal of Infectious Diseases, 2017, 216, S452-S457.	3.8	14
105	Minocycline Enhances the Antimicrobial Capacity of Unpolarized Macrophages Against Acinetobacter baumannii While Inducing an Anti-inflammatory Profile. Open Forum Infectious Diseases, 2017, 4, S134-S135.	0.8	1
106	Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	71
107	Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against Candida Species. Open Forum Infectious Diseases, 2017, 4, S298-S298.	0.8	0
108	Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis. PLoS Pathogens, 2017, 13, e1006763.	4.4	70

#	Article	IF	Citations
109	Traditional PK-PD Indices for Efficacy â€“ Can We Do Better?. Open Forum Infectious Diseases, 2017, 4, S298-S298.	0.8	4
110	Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	4.1	78
111	Bypass of Candida albicans Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1. PLoS Genetics, 2016, 12, e1006487.	3.2	46
112	Comparative In Vivo Pharmacokinetics/Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh Infection Model Against Staphylococcus aureus. Open Forum Infectious Diseases, 2016, 3, .	0.8	0
113	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). Open Forum Infectious Diseases, 2016, 3, .	0.8	2
114	Pleiotropic effects of the vacuolar ABC transporter MLT1 of Candida albicans on cell function and virulence. Biochemical Journal, 2016, 473, 1537-1552.	3.8	34
115	Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 3398-3406.	4.1	51
116	Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix. MBio, 2016, 7, .	4.4	258
117	Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. Nature Chemical Biology, 2016, 12, 867-875.	11.8	96
118	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorganic and Medicinal Chemistry, 2016, 24, 6390-6400.	2.6	92
119	The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplantâ€Associated Infection Surveillance Network (TRANSNET). Transplant Infectious Disease, 2016, 18, 921-931.	2.2	162
120	Global Identification of Biofilm-Specific Proteolysis in Candida albicans. MBio, 2016, 7, .	4.4	80
121	In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 4764-4769.	4.1	47
122	Intraluminal Release of an Antifungal Î²-Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection. ACS Biomaterials Science and Engineering, 2016, 2, 112-121.	5.3	33
123	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, 409-417.	5.2	1,343
124	Antifungal Agents. Infectious Disease Clinics of North America, 2016, 30, 51-83.	3.2	325
125	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, e1-e50.	5.2	3,405
126	Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions. PLoS Pathogens, 2016, 12, e1005828.	4.4	116

#	Article	IF	Citations
127	Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. Microbiology Spectrum, 2015, 3, .	3.6	55
128	Histoplasmosis Complicating Tumor Necrosis Factorâ€“Î± Blocker Therapy: A Retrospective Analysis of 98 Cases. Clinical Infectious Diseases, 2015, 61, 409-417.	5.2	134
129	Nontoxic antimicrobials that evade drug resistance. Nature Chemical Biology, 2015, 11, 481-487.	11.8	83
130	An expanded regulatory network temporally controls C andida albicans	2.5	165
131	Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1265-1272.	4.1	90
132	In Vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 1258-1264.	4.1	35
133	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). Medical Mycology, 2015, 53, 440-446.	0.6	99
134	Community participation in biofilm matrix assembly and function. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4092-4097.	7.5	165
135	The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: Highly selective cytotoxic agents. European Journal of Medicinal Chemistry, 2015, 105, 208-219.	5.3	49
136	In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 6568-6574.	4.1	27
137	Application of 3D NMR for Structure Determination of Peptide Natural Products. Journal of Organic Chemistry, 2015, 80, 8713-8719.	3.5	21
138	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	19.3	295
139	Host Contributions to Construction of Three Device-Associated Candida albicans Biofilms. Infection and Immunity, 2015, 83, 4630-4638.	2.7	70
140	Development of New Strategies for Echinocandins: Progress in Translational Research. Clinical Infectious Diseases, 2015, 61, S601-S603.	5.2	7
141	Antifungal Pharmacokinetics and Pharmacodynamics. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a019653-a019653.	6.6	108
142	Comparative Phenotypic Analysis of the Major Fungal Pathogens Candida parapsilosis and Candida albicans. PLoS Pathogens, 2014, 10, e1004365.	4.4	118
143	A Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in Candida albicans. MBio, 2014, 5, .	4.4	80
144	Novel Entries in a Fungal Biofilm Matrix Encyclopedia. MBio, 2014, 5, .	4.4	273

#	Article	IF	Citations
145	Fungal Biofilms, Drug Resistance, and Recurrent Infection. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a019729-a019729.	6.6	227
146	Daptomycin Dosing Based on Ideal Body Weight versus Actual Body Weight: Comparison of Clinical Outcomes. Antimicrobial Agents and Chemotherapy, 2014, 58, 88-93.	4.1	23
147	Searching for new derivatives of neocryptolepine: Synthesis, antiproliferative, antimicrobial and antifungal activities. European Journal of Medicinal Chemistry, 2014, 78, 304-313.	5.3	36
148	Forazolineâ€…A: Marineâ€Derived Polyketide with Antifungal Inâ€…Vivo Efficacy. Angewandte Chemie - International Edition, 2014, 53, 11583-11586.	14.4	114
149	Rat Indwelling Urinary Catheter Model of Candida albicans Biofilm Infection. Infection and Immunity, 2014, 82, 4931-4940.	2.7	42
150	Failure of Clindamycin To Eradicate Infection with Beta-Hemolytic Streptococci Inducibly Resistant to Clindamycin in an Animal Model and in Human Infections. Antimicrobial Agents and Chemotherapy, 2014, 58, 1327-1331.	4.1	17
151	Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004â€“2008. PLoS ONE, 2014, 9, e101510.	2.3	373
152	Synthesis and Antibacterial Activity of Doxycycline Neoglycosides. Journal of Natural Products, 2013, 76, 1627-1636.	3.6	19
153	Mechanisms of Candida Biofilm Drug Resistance. Future Microbiology, 2013, 8, 1325-1337.	2.0	382
154	The APSES transcription factor Efg1 is a global regulator that controls morphogenesis and biofilm formation in Candida parapsilosis. Molecular Microbiology, 2013, 90, 36-53.	2.5	53
155	Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 579-585.	4.1	71
156	Insights into fungal pathogenesis from the iatrogenic epidemic of Exserohilum rostratum fungal meningitis. Fungal Genetics and Biology, 2013, 61, 143-145.	2.1	17
157	Optimizing antifungal choice and administration. Current Medical Research and Opinion, 2013, 29, 13-18.	2.1	84
158	Regulatory Role of Glycerol in Candida albicans Biofilm Formation. MBio, 2013, 4, .	4.4	91
159	Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 5642-5648.	4.1	59
160	Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 105and 107CFU Injected into Opposite Thighs of Neutropenic Mice. Antimicrobial Agents and Chemotherapy, 2013, 57, 1434-1441.	4.1	50
161	Impact ofIn VivoTriazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy againstCyp51Mutant Isolates. Antimicrobial Agents and Chemotherapy, 2013, 57, 5438-5447.	4.1	32
162	Reply to Oude Lashof and Vogelaers. Clinical Infectious Diseases, 2013, 56, 1515-1516.	5.2	1

#	Article	IF	Citations
163	Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 6284-6289.	4.1	83
164	Preparation of Candida albicans Biofilms for Transmission Electron Microscopy. Bio-protocol, 2013, 3, .	0.4	4
165	Preparation of Candida albicans Biofilms Using an in vivo Rat Central Venous Catheter Model. Bio-protocol, 2013, 3, .	0.4	3
166	A Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance. PLoS Pathogens, 2012, 8, e1002848.	4.4	276
167	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. Clinical Infectious Diseases, 2012, 54, 1110-1122.	5.2	744
168	Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations. Antimicrobial Agents and Chemotherapy, 2012, 56, 5875-5882.	4.1	41
169	Comparative Pharmacodynamics of the New Oxazolidinone Tedizolid Phosphate and Linezolid in a Neutropenic Murine Staphylococcus aureus Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 5916-5922.	4.1	53
170	A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans. Cell, 2012, 148, 126-138.	33.7	691
171	Comparative analysis ofCandidabiofilm quantitation assays. Medical Mycology, 2012, 50, 214-218.	0.6	72
172	Identification and Characterization of Antifungal Compounds Using a Saccharomyces cerevisiae Reporter Bioassay. PLoS ONE, 2012, 7, e36021.	2.3	33
173	Protein Binding: Do We Ever Learn?. Antimicrobial Agents and Chemotherapy, 2011, 55, 3067-3074.	4.1	240
174	Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting. Critical Care Clinics, 2011, 27, 123-147.	2.0	54
175	Optimizing a Candida Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay. Journal of Clinical Microbiology, 2011, 49, 1426-1433.	4.0	141
176	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagnostic Microbiology and Infectious Disease, 2011, 70, 330-343.	1.6	126
177	Conserved and Divergent Roles of Bcr1 and CFEM Proteins in Candida parapsilosis and Candida albicans. PLoS ONE, 2011, 6, e28151.	2.3	87
178	Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation. Eukaryotic Cell, 2011, 10, 1660-1669.	2.7	153
179	Antifungal PK/PD Considerations in Fungal Pulmonary Infections. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 783-794.	2.3	22
180	Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia. Antimicrobial Agents and Chemotherapy, 2011, 55, 2113-2121.	4.1	111

#	Article	IF	Citations
181	Multilaboratory Testing of Two-Drug Combinations of Antifungals againstCandida albicans,Candida glabrata, andCandida parapsilosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 1543-1548.	4.1	47
182	Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathogens, 2011, 7, e1002257.	4.4	257
183	Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis. Eukaryotic Cell, 2011, 10, 803-819.	2.7	108
184	Comparison of In Vitro Susceptibility Characteristics of Candida Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. Journal of Clinical Microbiology, 2011, 49, 2404-2410.	4.0	59
185	The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses. Current Infectious Disease Reports, 2010, 12, 471-478.	2.6	7
186	Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene. Antimicrobial Agents and Chemotherapy, 2010, 54, 3505-3508.	4.1	209
187	Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis. Clinical Infectious Diseases, 2010, 50, 1559-1567.	5.2	296
188	Genetic Basis ofCandidaBiofilm Resistance Due to Drugâ€Sequestering Matrix Glucan. Journal of Infectious Diseases, 2010, 202, 171-175.	3.8	243
189	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001â€“2006: Overview of the Transplantâ€Associated Infection Surveillance Network (TRANSNET) Database. Clinical Infectious Diseases, 2010, 50, 1091-1100.	5.2	1,325
190	Development and Validation of an In Vivo Candida albicans Biofilm Denture Model. Infection and Immunity, 2010, 78, 3650-3659.	2.7	150
191	Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplantâ€Associated Infection Surveillance Network (TRANSNET). Clinical Infectious Diseases, 2010, 50, 1101-1111.	5.2	1,450
192	Biofilm Matrix Regulation by Candida albicans Zap1. PLoS Biology, 2009, 7, e1000133.	5.0	315
193	Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrobial Agents and Chemotherapy, 2009, 53, 24-34.	4.1	468
194	Voriconazole Use for Endemic Fungal Infections. Antimicrobial Agents and Chemotherapy, 2009, 53, 1648-1651.	4.1	137
195	Time Course Global Gene Expression Analysis of an In Vivo Candida Biofilm. Journal of Infectious Diseases, 2009, 200, 307-313.	3.8	166
196	GuÃas de prÃ¡ctica clÃ¬nica para el manejo de la candidiasis: actualizaciÃ³n del 2009, de la Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, T1-T35.	5.2	8
197	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 503-535.	5.2	2,727
198	Pharmacokineticâ€“pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagnostic Microbiology and Infectious Disease, 2009, 63, 409-414.	1.6	51

#	Article	IF	Citations
199	Combination Antifungal Therapy Involving Amphotericin B, Rapamycin and 5-Fluorocytosine Using PEG-Phospholipid Micelles. Pharmaceutical Research, 2008, 25, 2056-2064.	3.7	26
200	Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy. Current Fungal Infection Reports, 2008, 2, 12-19.	3.1	2
201	Review of techniques for diagnosis of catheter-related Candida biofilm infections. Current Fungal Infection Reports, 2008, 2, 237-243.	3.1	4
202	Complementary Adhesin Function in C. albicans Biofilm Formation. Current Biology, 2008, 18, 1017-1024.	3.6	329
203	Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method. Antimicrobial Agents and Chemotherapy, 2008, 52, 4175-4177.	4.1	43
204	Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 1127-1132.	4.1	224
205	Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2008, 52, 3022-3028.	4.1	149
206	Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant Staphylococcus aureus with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models. Antimicrobial Agents and Chemotherapy, 2008, 52, 2156-2162.	4.1	96
207	Reduced Biocide Susceptibility in Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 3411-3413.	4.1	65
208	In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin. Antimicrobial Agents and Chemotherapy, 2007, 51, 1633-1642.	4.1	113
209	CNS pharmacokinetics of antifungal agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 573-581.	2.7	107
210	Î²â€1,3 Glucan as a Test for Central Venous Catheter Biofilm Infection. Journal of Infectious Diseases, 2007, 195, 1705-1712.	3.8	89
211	Eap1p, an Adhesin That Mediates Candida albicans Biofilm Formation In Vitro and In Vivo. Eukaryotic Cell, 2007, 6, 931-939.	2.7	140
212	Clinical practice guideline: Adult sinusitis. Otolaryngology - Head and Neck Surgery, 2007, 137, .	2.3	802
213	Putative Role of Î²-1,3 Glucans in Candida albicans Biofilm Resistance. Antimicrobial Agents and Chemotherapy, 2007, 51, 510-520.	4.1	399
214	CNS pharmacokinetics of antifungal agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 573-581.	2.7	52
215	Pharmacology of Systemic Antifungal Agents. Clinical Infectious Diseases, 2006, 43, S28-S39.	5.2	272
216	Pharmacokinetics and Pharmacodynamics of Antifungals. Infectious Disease Clinics of North America, 2006, 20, 679-697.	3.2	97

#	Article	IF	Citations
217	Candida albicans biofilm development, modeling a hostâ€“pathogen interaction. Current Opinion in Microbiology, 2006, 9, 340-345.	7.0	207
218	Alcohol Dehydrogenase Restricts the Ability of the Pathogen Candida albicans To Form a Biofilm on Catheter Surfaces through an Ethanol-Based Mechanism. Infection and Immunity, 2006, 74, 3804-3816.	2.7	145
219	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	5.2	3
220	Critical Role of Bcr1-Dependent Adhesins in C. albicans Biofilm Formation In Vitro and In Vivo. PLoS Pathogens, 2006, 2, e63.	4.4	476
221	Fungal pathogenesis: Bridging the gap between the bedside and the bench. Mycopathologia, 2005, 159, 319-323.	2.5	1
222	The Microbe-Host Interface in Respiratory Tract Infections Edited by Jan L. L. Kimpen and Octavio Ramilo Wymondham, UK: Horizon Bioscience, 2005. 323 pp., illustrated. $139.95 (cloth). Clinical Infectious Diseases, 2005, 41, 767-768.	5.2	0
223	In Vivo Pharmacodynamic Activity of Daptomycin. Antimicrobial Agents and Chemotherapy, 2004, 48, 63-68.	4.1	373
224	Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clinics in Laboratory Medicine, 2004, 24, 477-502.	1.1	85
225	Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resistance Updates, 2004, 7, 185-194.	19.3	18
226	Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Current Opinion in Infectious Diseases, 2004, 17, 533-540.	3.4	42
227	Clinical pharmacodynamics of antifungals. Infectious Disease Clinics of North America, 2003, 17, 635-649.	3.2	27
228	In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. Antimicrobial Agents and Chemotherapy, 2003, 47, 1179-1186.	4.1	161
229	Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Current Opinion in Infectious Diseases, 2001, 14, 165-172.	3.4	43
230	Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo. Antimicrobial Agents and Chemotherapy, 1999, 43, 2473-2478.	4.1	68
231	PHARMACOKINETICS AND PHARMACODYNAMICS OF OUTPATIENT INTRAVENOUS ANTIMICROBIAL THERAPY. Infectious Disease Clinics of North America, 1998, 12, 849-860.	3.2	30
232	Pharmacodynamics of Fluoroquinolones in Experimental Models of Endocarditis. Clinical Infectious Diseases, 1998, 27, 47-50.	5.2	58
233	Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatric Infectious Disease Journal, 1996, 15, 255-259.	1.1	429
234	Pharmacokinetics and pharmacodynamics of antibiotics in otitis media*. Pediatric Infectious Disease Journal, 1996, 15, 944-948.	1.1	49

#	Article	IF	Citations
235	Evolution of the complex transcription network controlling biofilm formation in Candida species. ELife, 0, 10, .	1.6	41
236	Transcriptional rewiring over evolutionary timescales changes quantitative and qualitative properties of gene expression. ELife, 0, 5, .	1.6	66
237	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in Aspergillus fumigatus. PeerJ, 0, 1, e4.	0.0	72
238	Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts. Clinical Infectious Diseases, 0, 81, 1008-1014.	5.2	4
239	Ume6 protein complexes connect morphogenesis, adherence and hypoxic genes to shape Candida albicans biofilm architecture. Nature Microbiology, 0, 10, 2231-2244.	16.0	3
240	The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release. PLoS Pathogens, 0, 21, e1013519.	4.4	0
241	Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa. Open Forum Infectious Diseases, 0, 12, .	0.8	1
242	Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa : Brief Summary. Open Forum Infectious Diseases, 0, 12, .	0.8	0
243	Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development. Antimicrobial Agents and Chemotherapy, 0, 70, .	4.1	0